|
|
|
|
| Managing The Tech Stack In Today’s Trials | May 26 Join Chief Editor John Oncea and an expert panel as they discuss practical solutions to one of the industry's biggest operational challenges: making clinical technology work for trials, not against them. Registration is free. |
|
|
CELEBRATING CLINICAL TRIALS DAY |
|
|
|
By John Oncea, Clinical Tech Leader | Clinical Trials Day - championed by ACRP - is fast approaching, and this year’s theme, Research Rising, lands at a moment of genuine urgency. | |
|
|
|
|
By John Oncea, Clinical Tech Leader | Fragmented systems slow trials and raise risk. Learn what fuels clinical tech sprawl — and how sponsors can simplify, regain control, and move studies forward. | |
|
|
|
|
|
Where RWE Actually Improves Trials | By Clinical Tech Leader | Practical examples of RWE, according to Kathleen Mandziuk, include improving trial design, by refining I/E criteria, reducing patient burden, and using real-world behavior data. She highlights how mismatches between protocol demands and real patient lives can hurt recruitment and retention. |
|
|
|
|
How Automation Simplifies Drug Resupply At Sites | By Casey Doyle, Almac Clinical Technologies | Automated resupply replaces spreadsheets and guesswork with real‑time IRT logic, easing site workload, minimizing errors, and improving visibility across the trial supply chain. |
|
|
|
|
|
What HEOR Means For Clinical And Market Access Strategy | By ISPOR—The Professional Society for Health Economics and Outcomes Research | A practical look at HEOR and how it informs value demonstration, reimbursement strategy, and healthcare decision-making across the product lifecycle. |
|
|
|
|
| The DIA Global Annual Meeting creates a unique neutral ground where industry, regulators, academia, and patient advocates collaborate on shared challenges, accelerating solutions that no single sector could achieve alone. From early discovery to post-market surveillance, our programming tackles the full therapeutic lifecycle with insights that translate directly into faster more efficient pathways to patients. |
|
|
|
|
|
|
|
